Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Dexamethasone 51Aprepitant 39Palonosetron 37Ondansetron 31Granisetron 22Calcium Dobesilate 14fosaprepitant 13Olanzapine 13Therapeutics 8dexamethasone acetate 7ramosetron 6netupitant, palosentron drug combination 6casopitant 6Tropisetron 6Cyclophosphamide 6dexamethasone 21-phosphate 5Radiotherapy 5Metoclopramide 5Doxorubicin 5netupitant 4dolasetron 4Surveys and Questionnaires 4Dronabinol 4Acupressure 4Yoga 3Vincristine 3Tablets 3Psychiatric Rehabilitation 3Prochlorperazine 3Lorazepam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vomiting × Serotonin 5-HT3 Receptor Antagonists × Clear all
NCT04430361 2020-06-12

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡